Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2022-11-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司相关股东延长股份锁定期的专项核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed report from the underwriting and sponsorship institution (方正证券承销保荐有限责任公司) regarding the extension of the lock-up period for certain shareholders of Shanghai Sailun Biotechnology Co., Ltd. It references the company's initial public offering (IPO) on the Shanghai Stock Exchange Sci-Tech Innovation Board in March 2022 and discusses the shareholders' commitments to lock their shares for a specified period. The document includes specific shareholder names, shareholding amounts, original and extended lock-up expiration dates, and the rationale for the extension (triggered by the stock price being below the IPO price for a certain period). The document is a formal verification and opinion on the compliance of these lock-up extensions with regulatory and contractual commitments. It is not an announcement of a report publication, nor is it a financial report, earnings release, or management discussion. It is a specialized regulatory compliance report related to share lock-up periods and shareholder commitments, which does not fit neatly into categories like Annual Report, Earnings Release, or Capital Update. It is a regulatory filing related to compliance and shareholder lock-up verification. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (5158 characters) and content support this classification with high confidence.
2022-11-21 Chinese
赛伦生物：关于召开2022年第三季度业绩说明会的公告
Call Transcript Classification · 90% confidence The document is an announcement about the scheduling and details of a 2022 third quarter earnings conference call (业绩说明会) for Shanghai Serum Bio-Tech Co., Ltd. It includes the date, time, location, participation method, and contact information for the event. It does not contain actual financial results or detailed financial statements but rather informs investors about the upcoming interactive session to discuss the third quarter results. This matches the characteristics of a Call Transcript (CT) type document, which is a transcript or announcement related to earnings calls or investor calls. However, since this document is only an announcement of the call and not the transcript itself, it is best classified as a Call Transcript (CT) because it is specifically about the earnings explanation meeting. The document length is short (1514 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best fit is Call Transcript (CT).
2022-11-14 Chinese
赛伦生物：2022年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年第三季度报告" which translates to "2022 Third Quarter Report." It contains detailed financial data including income statements, balance sheets, cash flow statements, and shareholder information for the third quarter of 2022. The report explicitly states it is unaudited and covers the period from the start of the year to the end of the third quarter (nine months). The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length (15,000 characters) and detailed financial content confirm it is the report itself, not just an announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2022
2022-10-25 Chinese
赛伦生物：第三届监事会第七次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the Supervisory Board of Shanghai SAILUN Bio-technology Co., Ltd. regarding the resolution passed at the seventh meeting of the third Supervisory Board. The key content is the approval of the company's 2022 third quarter report. The announcement confirms that the report's preparation and review comply with relevant laws and regulations, and that the report is accurate and complete. However, the document itself does not contain the actual financial data or the full report but refers readers to the full 2022 third quarter report published on the Shanghai Stock Exchange website. The document length is short (790 characters), and it serves as a notice of the Supervisory Board's approval and the existence of the report rather than the report itself. According to the "Menu vs Meal" rule, this is an announcement about the report, not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a regulatory announcement that does not fit other specific categories and is not the full interim report itself.
2022-10-25 Chinese
赛伦生物：关于高级管理人员离职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management personnel (vice general manager) from the company Shanghai Sairen Biotechnology Co., Ltd. It details the resignation, effective date, shareholding information, and confirms no impact on normal operations. There is no financial data, no report or presentation attached, and it focuses solely on management change. This fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2022-09-26 Chinese
赛伦生物：关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) for investors. It mentions the date, time, location, and participation method for the meeting, which is a typical investor presentation event. The document does not contain actual financial statements or detailed financial analysis but rather invites investors to attend and ask questions. It is not the half-year report itself but an announcement about the meeting to discuss the half-year results. Therefore, it fits the category of Investor Presentation (IP). The document length is short and focused on the meeting details, not the report itself, so it is not an Interim/Quarterly Report (IR).
2022-09-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.